Logo

CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

Share this

M&A

CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

Shots:

  • Verastem will receive an upfront of $15M with up to $30M for development milestones- additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib)
  • CSPC to get exclusive development and commercialization rights of Copiktra in China and will also assist Verastem in R&D activities globally on cost sharing basis
  • Copiktra is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase)- first approved dual inhibitor of PI3K-delta and PI3K-gamma and received approval from FDA for the treatment of r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies

    Ref: Verastem Oncology | Image: Wall Street

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions